373 related articles for article (PubMed ID: 15090828)
1. Impact of 5 years of maximally successful highly active antiretroviral therapy on CD4 cell count and HIV-1 DNA level.
Viard JP; Burgard M; Hubert JB; Aaron L; Rabian C; Pertuiset N; Lourenço M; Rothschild C; Rouzioux C
AIDS; 2004 Jan; 18(1):45-9. PubMed ID: 15090828
[TBL] [Abstract][Full Text] [Related]
2. Cellular proviral HIV-DNA decline and viral isolation in naïve subjects with <5000 copies/ml of HIV-RNA and >500 x 10(6)/l CD4 cells treated with highly active antiretroviral therapy.
Andreoni M; Parisi SG; Sarmati L; Nicastri E; Ercoli L; Mancino G; Sotgiu G; Mannazzu M; Trevenzoli M; Tridente G; Concia E; Aceti A
AIDS; 2000 Jan; 14(1):23-9. PubMed ID: 10714564
[TBL] [Abstract][Full Text] [Related]
3. Plasma cytomegalovirus DNA, pp65 antigenaemia and a low CD4 cell count remain risk factors for cytomegalovirus disease in patients receiving highly active antiretroviral therapy.
Salmon-Céron D; Mazeron MC; Chaput S; Boukli N; Senechal B; Houhou N; Katlama C; Matheron S; Fillet AM; Gozlan J; Leport C; Jeantils V; Freymuth F; Costagliola D
AIDS; 2000 May; 14(8):1041-9. PubMed ID: 10853987
[TBL] [Abstract][Full Text] [Related]
4. Quantification of integrated and total HIV-1 DNA after long-term highly active antiretroviral therapy in HIV-1-infected patients.
Ibáñez A; Puig T; Elias J; Clotet B; Ruiz L; Martínez MA
AIDS; 1999 Jun; 13(9):1045-9. PubMed ID: 10397534
[TBL] [Abstract][Full Text] [Related]
5. [Treatment interruption in 30 HIV-infected patients with successful viral suppression under highly active antiretroviral treatment].
Pavie J; Porcher R; Fournier S; André F; Tournoux C; Palmer P; Rabian C; Jean-Michel M
Presse Med; 2005 Jun; 34(10 Suppl):1S8-13. PubMed ID: 16025661
[TBL] [Abstract][Full Text] [Related]
6. Long-term immunological response in HIV-1-infected subjects receiving potent antiretroviral therapy.
Kaufmann GR; Bloch M; Zaunders JJ; Smith D; Cooper DA
AIDS; 2000 May; 14(8):959-69. PubMed ID: 10853977
[TBL] [Abstract][Full Text] [Related]
7. Proviral HIV-1 DNA in subjects followed since primary HIV-1 infection who suppress plasma viral load after one year of highly active antiretroviral therapy.
Ngo-Giang-Huong N; Deveau C; Da Silva I; Pellegrin I; Venet A; Harzic M; Sinet M; Delfraissy JF; Meyer L; Goujard C; Rouzioux C;
AIDS; 2001 Apr; 15(6):665-73. PubMed ID: 11371680
[TBL] [Abstract][Full Text] [Related]
8. Treatment with highly active antiretroviral therapy in human immunodeficiency virus type 1-infected children is associated with a sustained effect on growth.
Verweel G; van Rossum AM; Hartwig NG; Wolfs TF; Scherpbier HJ; de Groot R
Pediatrics; 2002 Feb; 109(2):E25. PubMed ID: 11826235
[TBL] [Abstract][Full Text] [Related]
9. Impact of nucleoside reverse transcriptase inhibitors on mitochondria in human immunodeficiency virus type 1-infected children receiving highly active antiretroviral therapy.
Saitoh A; Fenton T; Alvero C; Fletcher CV; Spector SA
Antimicrob Agents Chemother; 2007 Dec; 51(12):4236-42. PubMed ID: 17893156
[TBL] [Abstract][Full Text] [Related]
10. Three-year effectiveness of highly active antiretroviral treatment in the Luxembourg HIV cohort.
Servais J; Schmit JC; Arendt V; Lambert C; Staub T; Robert I; Fontaine E; Plesséria JM; Burgy C; Kirpach P; Schneider F; Hemmer R
HIV Clin Trials; 2000; 1(2):17-24. PubMed ID: 11590494
[TBL] [Abstract][Full Text] [Related]
11. Increase of HIV-1 pro-viral DNA per million peripheral blood mononuclear cells in patients with advanced HIV disease (CD4<200 cells/mm3) receiving interleukin 2 combined with HAART versus HAART alone (ANRS-082 trial).
Delaugerre C; Gourlain K; Tubiana R; Carcelain G; Marcelin AG; Chouquet C; Mouroux M; Duvivier C; Autran B; Costagliola D; Katlama C; Calvez V
Antivir Ther; 2003 Jun; 8(3):233-7. PubMed ID: 12924540
[TBL] [Abstract][Full Text] [Related]
12. Persistence of human immunodeficiency virus (HIV) type 1 DNA in peripheral blood despite prolonged suppression of plasma HIV-1 RNA in children.
Saitoh A; Hsia K; Fenton T; Powell CA; Christopherson C; Fletcher CV; Starr SE; Spector SA
J Infect Dis; 2002 May; 185(10):1409-16. PubMed ID: 11992275
[TBL] [Abstract][Full Text] [Related]
13. Can highly active antiretroviral therapy be interrupted in patients with sustained moderate HIV RNA and > 400 CD4+ cells/microl? Impact on immunovirological parameters.
Pellegrin I; Thiébaut R; Blanco P; Viallard JF; Schrive MH; Merel P; Chêne G; Fleury H; Moreau JF; Pellegrin JL
J Med Virol; 2005 Oct; 77(2):164-72. PubMed ID: 16121362
[TBL] [Abstract][Full Text] [Related]
14. HIV-1 DNA proviral load in treated and untreated HIV-1 seropositive patients.
Re MC; Vitone F; Biagetti C; Schiavone P; Alessandrini F; Bon I; de Crignis E; Gibellini D
Clin Microbiol Infect; 2010 Jun; 16(6):640-6. PubMed ID: 19732081
[TBL] [Abstract][Full Text] [Related]
15. Continued CD4 cell count increases in HIV-infected adults experiencing 4 years of viral suppression on antiretroviral therapy.
Hunt PW; Deeks SG; Rodriguez B; Valdez H; Shade SB; Abrams DI; Kitahata MM; Krone M; Neilands TB; Brand RJ; Lederman MM; Martin JN
AIDS; 2003 Sep; 17(13):1907-15. PubMed ID: 12960823
[TBL] [Abstract][Full Text] [Related]
16. Virological and immunological responses to HAART in asymptomatic therapy-naive HIV-1-infected subjects according to CD4 cell count.
Rizzardi GP; Tambussi G; Bart PA; Chapuis AG; Lazzarin A; Pantaleo G
AIDS; 2000 Oct; 14(15):2257-63. PubMed ID: 11089613
[TBL] [Abstract][Full Text] [Related]
17. Long-term survival and immuno-virological response of African HIV-1-infected children to highly active antiretroviral therapy regimens.
Rouet F; Fassinou P; Inwoley A; Anaky MF; Kouakoussui A; Rouzioux C; Blanche S; Msellati P;
AIDS; 2006 Nov; 20(18):2315-9. PubMed ID: 17117017
[TBL] [Abstract][Full Text] [Related]
18. Effects of nucleoside reverse transcriptase inhibitor backbone on the efficacy of first-line boosted highly active antiretroviral therapy based on protease inhibitors: meta-regression analysis of 12 clinical trials in 5168 patients.
Hill A; Sawyer W
HIV Med; 2009 Oct; 10(9):527-35. PubMed ID: 19785663
[TBL] [Abstract][Full Text] [Related]
19. Immunological and virological responses to highly active antiretroviral therapy in a non-clinical trial setting in a developing Caribbean country.
Kilaru KR; Kumar A; Sippy N; Carter AO; Roach TC
HIV Med; 2006 Mar; 7(2):99-104. PubMed ID: 16420254
[TBL] [Abstract][Full Text] [Related]
20. Residual viraemia in subjects with chronic HIV infection and viral load < 50 copies/ml: the impact of highly active antiretroviral therapy.
Palmisano L; Giuliano M; Nicastri E; Pirillo MF; Andreotti M; Galluzzo CM; Bucciardini R; Fragola V; Andreoni M; Vella S
AIDS; 2005 Nov; 19(16):1843-7. PubMed ID: 16227792
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]